[go: up one dir, main page]

MX2018002906A - Metodos de tratamiento de trastornos del desarrollo con pipradrol. - Google Patents

Metodos de tratamiento de trastornos del desarrollo con pipradrol.

Info

Publication number
MX2018002906A
MX2018002906A MX2018002906A MX2018002906A MX2018002906A MX 2018002906 A MX2018002906 A MX 2018002906A MX 2018002906 A MX2018002906 A MX 2018002906A MX 2018002906 A MX2018002906 A MX 2018002906A MX 2018002906 A MX2018002906 A MX 2018002906A
Authority
MX
Mexico
Prior art keywords
methods
pipradrol
developmental disorders
treating developmental
syndrome
Prior art date
Application number
MX2018002906A
Other languages
English (en)
Inventor
During Matthew
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of MX2018002906A publication Critical patent/MX2018002906A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan métodos para tratar trastornos del desarrollo administrando una composición farmacéutica de pipradrol o una sal farmacéuticamente aceptable del mismo. Los métodos se pueden usar para tratar condiciones como epilepsia, síndrome de Landau-Kleffner, síndrome de Lennox-Gastaut (LGS) y el síndrome de Dravet.
MX2018002906A 2015-09-09 2016-09-08 Metodos de tratamiento de trastornos del desarrollo con pipradrol. MX2018002906A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562215831P 2015-09-09 2015-09-09
US14/876,110 US9351968B1 (en) 2015-09-09 2015-10-06 Methods of treating developmental disorders using pipradrol
US15/147,429 US20170065572A1 (en) 2015-09-09 2016-05-05 Methods of treating developmental disorders using pipradrol
PCT/US2016/050702 WO2017044578A1 (en) 2015-09-09 2016-09-08 Methods of treating developmental disorders using pipradrol

Publications (1)

Publication Number Publication Date
MX2018002906A true MX2018002906A (es) 2018-06-08

Family

ID=56027680

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002906A MX2018002906A (es) 2015-09-09 2016-09-08 Metodos de tratamiento de trastornos del desarrollo con pipradrol.

Country Status (12)

Country Link
US (4) US9351968B1 (es)
EP (1) EP3331527A4 (es)
JP (1) JP2018528215A (es)
KR (1) KR20180081710A (es)
CN (1) CN108366999A (es)
AU (1) AU2016318943A1 (es)
BR (1) BR112018004680A2 (es)
CA (1) CA2997923A1 (es)
HK (1) HK1255132A1 (es)
IL (3) IL257944B (es)
MX (1) MX2018002906A (es)
WO (1) WO2017044578A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
IL256912B2 (en) 2015-07-17 2024-01-01 Ovid Therapeutics Inc Methods of treating developmental disorders with gaboxadol
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
CA3002831C (en) 2015-10-22 2024-04-16 Cavion, Inc. Methods for treating angelman syndrome and related disorders
KR20190013737A (ko) 2016-05-26 2019-02-11 오비드 테라퓨틱스 인크. 피프라드롤을 이용한 행동 증후군들의 치료 방법들
CN109715151A (zh) 2016-08-11 2019-05-03 奥维德医疗公司 用于治疗癫痫性紊乱的方法和组合物
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
SG11201909960UA (en) 2017-04-26 2019-11-28 Cavion Inc Methods for improving memory and cognition and for treating memory and cognitive disorders
SG11201909963YA (en) * 2017-04-26 2019-11-28 Cavion Inc Methods for treating dravet syndrome
AU2018309049A1 (en) 2017-08-04 2020-02-27 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions
IL274431B2 (en) * 2017-11-14 2024-06-01 Sk Biopharmaceuticals Co Ltd Use of carbamate compound for reducing or treating developmental disorders including fragile x syndrome, angelman syndrome or rett syndrome
EP3833351A4 (en) 2018-09-20 2021-10-13 Ovid Therapeutics Inc. USE OF GABOXADOL FOR THE TREATMENT OF GILLES DE LA TOURETTE SYNDROME, TICS AND STATTING
BR112021006398A2 (pt) 2018-10-03 2021-07-06 Cavion Inc tratamento de tremor essencial usando (r)-2-(4-isopropilfenil)-n-(1-(5-(2,2,2-trifluoretoxi)piridin-2-il)etil) acetamida
WO2020106927A1 (en) 2018-11-21 2020-05-28 Certego Therapeutics Gaboxadol for reducing risk of suicide and rapid relief of depression
US11690829B2 (en) 2018-12-17 2023-07-04 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830083A (en) 1953-04-29 1958-04-08 Allied Chem & Dye Corp Production of aryloxy aliphatic carboxylic acids
US3947579A (en) 1974-06-03 1976-03-30 Nelson Research & Development Company Method and composition for potentiating neuroleptic drugs
US4084000A (en) 1975-07-16 1978-04-11 Nelson Research And Development Company Method of treating schizophrenia
US4129652A (en) 1976-08-16 1978-12-12 Nelson Research & Development Company Method for potentiating neuroleptic drugs
WO2003013514A1 (en) * 2001-08-08 2003-02-20 Carn-Aware Llc Improving neurological functions
WO2008095221A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of adhd
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
AU2009270799B2 (en) 2008-07-18 2016-05-19 Zafgen, Inc. Methods of treating an overweight or obese subject
FR2935611B1 (fr) 2008-09-10 2010-10-15 Commissariat Energie Atomique Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
ES2595251T3 (es) 2010-05-25 2016-12-28 Inserm - Institut National De La Santé Et De La Recherche Médicale Métodos y composición farmacéutica para el tratamiento de un trastorno alimentario con inicio temprano en un paciente
GB201111712D0 (en) * 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
KR20190013737A (ko) * 2016-05-26 2019-02-11 오비드 테라퓨틱스 인크. 피프라드롤을 이용한 행동 증후군들의 치료 방법들

Also Published As

Publication number Publication date
US20170065572A1 (en) 2017-03-09
US20180147195A1 (en) 2018-05-31
US20170216269A1 (en) 2017-08-03
US9913833B2 (en) 2018-03-13
CN108366999A (zh) 2018-08-03
EP3331527A4 (en) 2019-04-10
IL282655A (en) 2021-06-30
JP2018528215A (ja) 2018-09-27
WO2017044578A1 (en) 2017-03-16
IL257944A (en) 2018-05-31
IL282580A (en) 2021-06-30
BR112018004680A2 (pt) 2018-09-25
KR20180081710A (ko) 2018-07-17
CA2997923A1 (en) 2017-03-16
AU2016318943A1 (en) 2018-04-05
HK1255132A1 (zh) 2019-08-09
EP3331527A1 (en) 2018-06-13
IL257944B (en) 2021-05-31
US9351968B1 (en) 2016-05-31

Similar Documents

Publication Publication Date Title
MX2018002906A (es) Metodos de tratamiento de trastornos del desarrollo con pipradrol.
NZ730809A (en) Methods for treating filoviridae virus infections
MX2018000419A (es) Derivados de amida sustituida que tienen actividad multimodal contra el dolor.
MX2019012285A (es) Metodos de tratamiento de encefalopatias del desarrollo.
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
PH12016500978A1 (en) Piperazine derivatives having multimodal activity against pain
EA201692043A1 (ru) Лекарственная форма иммунодепрессанта
EP3176163A4 (en) Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient
MX2018013973A (es) Metodos de tratamiento de sindromes de comportamiento usando pipradrol.
MX2016006604A (es) Derivados de piperidina con actividad multimodal contra el dolor.
MX2022006304A (es) Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
TN2019000032A1 (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
EP4480577A3 (en) Structured elements and methods of use
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX2017006513A (es) Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor.
PH12018500814A1 (en) Oxadiazaspiro compounds for the treatment of drug abuse and addiction
AU2012280776B2 (en) Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases
MX2017013281A (es) Metodos para tratar transtornos del almacenamiento lisosomal.
PH12017501735B1 (en) Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same
WO2015138761A3 (en) Methods for treating peripheral nerve damage
WO2015027121A3 (en) Cancer treatment
MX2014014814A (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
PH12018500682A1 (en) Oxa-diazaspiro compounds having activity against pain
MX2018004774A (es) Derivados de morfolina sustituidos que tienen actividad contra el dolor.